CellCarta Strengthens its Histological Biomarker Franchise b

CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences


Reveal Biosciences Logo (CNW Group/CellCarta)
MONTREAL, May 11, 2021 /PRNewswire/ - CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ("Reveal"), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta's position as a leading provider of histopathology biomarker services and will enable the company to broaden its offering in AI-enabled multi-omic data analysis services and applications.
Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance research, clinical trials, and improve patient outcomes globally.  Reveal's imageDx™ pathology platform combines cutting edge machine learning (ML)-AI with traditional histopathology to transform tissue biology into actionable data.  Reveal's unique proprietary pipeline architecture and biomarker-based training methods also enable the development of scalable custom AI models for specific pathology endpoints, companion diagnostics and predictive models integrating multi-omic data. 

Related Keywords

China , Australia , California , United States , Montreal , Quebec , Canada , Belgium , Claire Weston , Martin Leblanc , Life Sciences , Reveal Biosciences , San Diego California , Pathology Intelligence , சீனா , ஆஸ்திரேலியா , கலிஃபோர்னியா , ஒன்றுபட்டது மாநிலங்களில் , மான்ட்ரியல் , க்வீபெக் , கனடா , பெல்ஜியம் , கிளாரி வெஸ்டன் , மார்டின் லெப்ளாங்க் , வாழ்க்கை அறிவியல் , வெளிப்படுத்து உயிர் அறிவியல் , சான் டியாகோ கலிஃபோர்னியா ,

© 2025 Vimarsana